Profile data is unavailable for this security.
About the company
Mendus AB (publ), formerly Immunicum AB, is a Sweden-based company that is engaged in the biopharmaceutical sector. The Company develops immunotherapy for therapeutic treatment of cancer and infectious diseases. The Company develops off-the-shelf, cell-based products that are immunogenic based on underlying allogeneic dendritic cell biology and which have the potential to activate the patient’s own immune system against cancer. The Company’s programs ilixadencel and DCP-001 are derived from healthy donor material and from Company's DCOne cell line, respectively. The Company develops ilixadencel to address the tumor burden of established tumors via intratumoral immune priming and DCP-001 as a cancer relapse vaccine, aimed at the reduction of tumor recurrence following initial treatment. Mendus has offices in Sweden and the Netherlands.
- Revenue in SEK (TTM)0.00
- Net income in SEK-101.62m
- Incorporated2002
- Employees30.00
- LocationMendus AB (publ)Ostermalmstorg 5STOCKHOLM 111 53SwedenSWE
- Phone+46 87328400
- Websitehttps://mendus.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Herantis Pharma Oyj | 0.00 | 3.27m | 341.26m | 10.00 | 115.35 | 6.19 | 104.46 | -- | 0.0126 | 0.0126 | 0.00 | 0.2344 | 0.00 | -- | -- | 0.00 | 4.31 | -80.46 | 6.16 | -104.37 | -- | -- | -- | -- | -- | -- | 0.0073 | -- | -- | -- | 103.00 | -- | -- | -- |
| INIFY Laboratories AB | 1.19m | -53.33m | 411.78m | -- | -- | 4.84 | -- | 345.16 | -1.19 | -1.19 | 0.0266 | 1.89 | -- | -- | -- | -- | -- | -- | -- | -- | 71.50 | -- | -4,470.08 | -- | -- | -- | -- | -- | -- | -- | -20.76 | -- | -- | -- |
| Bergenbio ASA | 351.55k | -189.09m | 432.02m | 18.00 | -- | 3.41 | -- | 1,228.90 | -0.2647 | -0.2647 | 0.0002 | 0.0474 | 0.0021 | -- | -- | -- | -111.66 | -66.15 | -176.09 | -78.74 | -- | -- | -53,785.59 | -11,419.44 | -- | -- | 0.00 | -- | -9.00 | -31.43 | 36.98 | -- | -- | -- |
| Initiator Pharma A/S | 0.00 | -35.78m | 467.79m | 3.00 | -- | 26.57 | -- | -- | -0.6584 | -0.6584 | 0.00 | 0.3328 | 0.00 | -- | -- | 0.00 | -58.55 | -65.10 | -62.50 | -70.59 | -- | -- | -- | -- | -- | -- | 0.5804 | -- | -- | -- | 40.52 | -- | -- | -- |
| Ascelia Pharma AB | 0.00 | -109.29m | 468.56m | 13.00 | -- | 6.51 | -- | -- | -3.20 | -3.20 | 0.00 | 2.13 | 0.00 | -- | -- | 0.00 | -71.51 | -- | -85.53 | -- | -- | -- | -- | -- | -- | -- | 0.0141 | -- | -- | -- | 16.72 | -- | -- | -- |
| Mendus AB (publ) | 0.00 | -101.62m | 512.66m | 30.00 | -- | 0.6234 | -- | -- | -0.2566 | -0.2566 | 0.00 | 0.8165 | 0.00 | -- | -- | 0.00 | -14.77 | -18.84 | -15.78 | -20.21 | -- | -- | -- | -28,474.53 | -- | -- | 0.0325 | -- | -100.00 | -- | 26.78 | -- | -- | -- |
| Lifecare AS | 17.18m | -24.70m | 528.37m | -- | -- | 11.28 | -- | 30.76 | -0.1995 | -0.1995 | 0.1396 | 0.3496 | 0.3753 | -- | 27.43 | -- | -53.96 | -41.60 | -60.93 | -47.04 | -- | -- | -143.78 | -147.96 | -- | -67.84 | 0.155 | -- | 1,284.20 | 109.30 | -10.08 | -- | -- | -- |
| Promimic AB | 37.07m | -9.22m | 531.73m | 17.00 | -- | 6.93 | -- | 14.34 | -0.5295 | -0.5295 | 2.08 | 4.11 | 0.3994 | -5.63 | 3.00 | 2,180,588.00 | -9.93 | -24.88 | -11.67 | -29.25 | 103.90 | 101.23 | -24.87 | -89.46 | 3.98 | -- | -- | -- | 128.63 | -- | 41.95 | -- | -- | -- |
| Gentian Diagnostics ASA | 134.22m | -10.57m | 551.37m | 58.00 | -- | 3.79 | -- | 4.11 | -0.6905 | -0.6905 | 8.76 | 9.51 | 0.7329 | 1.76 | 7.47 | 2,330,224.00 | -5.77 | -10.76 | -6.62 | -11.86 | 50.61 | 41.46 | -7.88 | -26.99 | 4.13 | -- | 0.0817 | -- | 32.98 | 27.63 | 54.92 | -- | -4.92 | -- |
| Xbrane Biopharma AB | 238.73m | -322.03m | 556.73m | 93.00 | -- | 0.5586 | -- | 2.33 | -1.27 | -1.52 | 0.943 | 0.6516 | 0.3553 | 2.59 | 357.65 | 2,566,979.00 | -47.92 | -40.98 | -82.48 | -67.24 | 14.82 | -- | -134.89 | -364.40 | 1.09 | -- | 0.2466 | -- | 314.33 | 63.42 | -91.10 | -- | 60.02 | -- |
| Enzymatica AB (publ) | 50.90m | -49.73m | 586.03m | 21.00 | -- | 7.25 | -- | 11.51 | -0.3027 | -0.3027 | 0.3099 | 0.4664 | 0.339 | 1.66 | 3.98 | -- | -33.12 | -27.36 | -35.04 | -33.98 | 62.59 | 65.08 | -97.69 | -66.12 | -- | -26.45 | 0.1909 | -- | 4.00 | -0.6382 | 27.57 | -- | 7.02 | -- |
| Orexo AB | 638.60m | -128.40m | 597.02m | 116.00 | -- | 10.06 | -- | 0.9349 | -3.73 | -3.73 | 18.55 | 1.71 | 0.6738 | 1.52 | 2.88 | 5,505,173.00 | -13.55 | -6.41 | -20.60 | -9.99 | 86.09 | 86.76 | -20.11 | -11.83 | 1.58 | 0.3604 | 0.8894 | -- | 2.32 | -3.99 | 27.76 | -- | 25.77 | -- |
| IRLAB Therapeutics AB | 5.68m | -177.84m | 657.72m | 37.00 | -- | 5.69 | -- | 115.84 | -3.43 | -3.43 | 0.1095 | 2.23 | 0.0227 | -- | 0.5137 | -- | -71.04 | -27.12 | -82.41 | -30.42 | -2,161.57 | -72.18 | -3,132.07 | -155.57 | -- | -- | 0.1923 | -- | -90.71 | 216.07 | -56.82 | -- | -22.56 | -- |
| Intellego Technologies AB | 186.49m | 59.61m | 687.80m | 68.00 | 11.04 | 4.55 | 10.89 | 3.69 | 2.36 | 2.36 | 7.43 | 5.74 | 0.8841 | 3.26 | 3.69 | 2,742,544.00 | 28.26 | -- | 44.00 | -- | 68.73 | -- | 31.96 | -- | 1.97 | 5.82 | 0.1684 | -- | 222.74 | -- | 493.56 | -- | -- | -- |
| Cantargia AB | 0.00 | -280.03m | 698.38m | 22.00 | -- | 4.14 | -- | -- | -1.65 | -1.65 | 0.00 | 0.9186 | 0.00 | -- | -- | 0.00 | -80.18 | -55.08 | -100.27 | -61.35 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 24.69 | -- | -- | -- |
Data as of Apr 19 2024. Currency figures normalised to Mendus AB (publ)'s reporting currency: Swedish Krona SEK
5.08%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Fj�rde AP-fondenas of 31 Dec 2022 | 21.25m | 3.15% |
| SEB Investment Management ABas of 28 Mar 2024 | 6.62m | 0.98% |
| Handelsbanken Fonder ABas of 31 Mar 2024 | 5.13m | 0.76% |
| FCG Fonder ABas of 31 Dec 2022 | 677.88k | 0.10% |
| WBS H�nicke Verm�gensverwaltung GmbHas of 31 Dec 2023 | 538.80k | 0.08% |
| Storebrand Asset Management ASas of 31 Jan 2024 | 33.33k | 0.01% |
| Skandia Investment Management ABas of 29 Feb 2024 | 32.42k | 0.01% |
| Case Kapitalf�rvaltning ABas of 30 Nov 2022 | 10.86k | 0.00% |
More ▼
Data from 31 Dec 2022 - 31 Jan 2024Source: FactSet Research Systems Inc.
